1327-53-3

IARC Cancer Review: Group 1 IMEMDT  .Animal Inadequate Evidence IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 2 (1973),p. 48 ; IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 23 (1980),p. 39. Reported in EPA TSCA Inventory. Arsenic and its compounds are on the Community Right-To-Know List. EPA Extremely Hazardous Substances List.

OSHA PEL: TWA 0.01 mg(As)/m³; Cancer Hazard
ACGIH TLV: TWA 0.01 mg/m³; Confirmed Human Carcinogen; BEI: 35 μ (As)/L inorganic arsenic and methylated metabolites in urine
DFG MAK: Human Carcinogen
NIOSH REL: CL 2 μg(As)/m³/15 M
DOT Classification:  6.1; Label: Poison

For occupational chemical analysis use NIOSH: Arsenic Trioxide, 7901.

The Arsenic(III) oxide, with the CAS registry number 1327-53-3, is also known as Acide arsenieux. It belongs to the product categories of Industrial/Fine Chemicals; Inorganics. Its EINECS registry number is 215-481-4. This chemical's molecular formula is As₂O₃ and molecular weight is 197.8414. Its systematic name is called bicyclo[1.1.1]diarsoxane. What's more, this chemical's classification codes are Agricultural Chemical; Antineoplastic Agents; Drug / Therapeutic Agent; Human Data; Insecticide; Mutation data; Out-dated Pesticide; Reproductive Effect; Rodenticide; Treatment of acute promyelocytic leukemia; Tumor data. This commercially important oxide of arsenic is the main precursor to other arsenic compounds, including organoarsenic compounds.

Preparation of Arsenic(III) oxide: this chemical can be generated via many routine processing of arsenic compounds including the oxidation (combustion) of arsenic and arsenic-containing minerals in air. Illustrative is the roasting of orpiment, a typical arsenic sulfide ore.

2 As₂S₃ + 9 O₂ → 2 As₂O₃ + 6 SO₂

Uses of Arsenic(III) oxide: this chemical can be used for refining element arsenic. In addition, it also can be used as clarify agent and decoloring agent in glass industry. On the other hand, Arsenic(III) oxide can be used as analytics reagents, such as reference reagent, reductant and antiseptic. Meanwhile, this chemical also can be used in the preparation of arsenic acid salt.

When you are using this chemical, please be cautious about it as the following:
This chemical is very toxic and is dangerous for the environment. Firstly, it is very toxic if swallowed. Secondly, Arsenic(III) oxide can cause burns and cancer. In case of accident or if you feel unwell seek medical advice immediately (show the label where possible). This material and its container must be disposed of as hazardous waste.

You can still convert the following datas into molecular structure:
(1)SMILES: O1[As]2O[As]1O2
(2)InChI: InChI=1/As2O3/c3-1-4-2(3)5-1
(3)InChIKey: GOLCXWYRSKYTSP-UHFFFAOYAM

The toxicity data is as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
cattle	LDLo	oral	30mg/kg (30mg/kg)		"Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1306, 1935.
chicken	LDLo	intradermal	13mg/kg (13mg/kg)		"Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1306, 1935.
dog	LDLo	intradermal	2mg/kg (2mg/kg)		"Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1306, 1935.
dog	LDLo	oral	10mg/kg (10mg/kg)		"Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1306, 1935.
human	LDLo	oral	1429ug/kg (1.429mg/kg)		Yakkyoku. Pharmacy. Vol. 31, Pg. 1247, 1980.
man	LDLo	oral	29mg/kg (29mg/kg)	BEHAVIORAL: SLEEP BEHAVIORAL: MUSCLE WEAKNESS GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Annals of Emergency Medicine. Vol. 16, Pg. 702, 1987.
man	LDLo	oral	114mg/kg (114mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED	Human & Experimental Toxicology. Vol. 18, Pg. 640, 1999.
man	LDLo	oral	123mg/kg (123mg/kg)	BRAIN AND COVERINGS: OTHER DEGENERATIVE CHANGES GASTROINTESTINAL: NAUSEA OR VOMITING LIVER: OTHER CHANGES	Journal of Forensic Sciences. Vol. 36, Pg. 1163, 1992.
man	LDLo	oral	286mg/kg (286mg/kg)	CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) LIVER: LIVER FUNCTION TESTS IMPAIRED MUSCULOSKELETAL: OTHER CHANGES	Journal of Toxicology, Clinical Toxicology. Vol. 29, Pg. 45, 1991.
man	LDLo	oral	2857mg/kg (2857mg/kg)	BEHAVIORAL: COMA KIDNEY, URETER, AND BLADDER: RENAL FUNCTION TESTS DEPRESSED LIVER: FATTY LIVER DEGERATION	Journal of Toxicology, Clinical Toxicology. Vol. 29, Pg. 131, 1991.
man	LDLo	unreported	2941ug/kg (2.941mg/kg)		"Poisoning; Toxicology, Symptoms, Treatments," 2nd ed., Arena, J.M., Springfield, IL, C.C. Thomas, 1970Vol. 2, Pg. 73, 1970.
man	TDLo	oral	14857ug/kg (14.857mg/kg)	SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)"	Journal of Toxicology, Clinical Toxicology. Vol. 36, Pg. 27, 1998.
mouse	LD50	intravenous	10700ug/kg (10.7mg/kg)		Proceedings of the Society for Experimental Biology and Medicine. Vol. 78, Pg. 392, 1951.
mouse	LD50	oral	31500ug/kg (31.5mg/kg)		Zhonghua Yufangyixue Zazhi. Chinese Journal of Preventive Medicine. Vol. 14, Pg. 86, 1980.
mouse	LD50	subcutaneous	9800ug/kg (9.8mg/kg)		Proceedings of the Society for Experimental Biology and Medicine. Vol. 78, Pg. 392, 1951.
pigeon	LDLo	intradermal	100mg/kg (100mg/kg)		"Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1306, 1935.
rabbit	LD50	oral	20190ug/kg (20.19mg/kg)		Zhonghua Yufangyixue Zazhi. Chinese Journal of Preventive Medicine. Vol. 22, Pg. 284, 1988.
rabbit	LDLo	intravenous	10560ug/kg (10.56mg/kg)	LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: OTHER CHANGES	Biochemische Zeitschrift. Vol. 70, Pg. 144, 1915.
rat	LD50	intraperitoneal	871mg/kg (871mg/kg)		Gigiena Truda i Professional'nye Zabolevaniya. Labor Hygiene and Occupational Diseases. Vol. 19(3), Pg. 30, 1975.
rat	LD50	oral	14600ug/kg (14.6mg/kg)		Gigiena i Sanitariya. For English translation, see HYSAAV. Vol. 52(1), Pg. 21, 1987.
rat	LDLo	subcutaneous	8mg/kg (8mg/kg)	SKIN AND APPENDAGES (SKIN): CORROSIVE: AFTER TOPICAL EXPOSURE	Journal of Pharmacology and Experimental Therapeutics. Vol. 19, Pg. 337, 1922.
rat	LDLo	unreported	8mg/kg (8mg/kg)		Biochemische Zeitschrift. Vol. 184, Pg. 360, 1927.
women	TDLo	oral	20mg/kg (20mg/kg)	GASTROINTESTINAL: NAUSEA OR VOMITING GASTROINTESTINAL: OTHER CHANGES	International Archives of Occupational and Environmental Health. Vol. 68, Pg. 342, 1996.
women	TDLo	oral	100mg/kg (100mg/kg)	CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION GASTROINTESTINAL: NAUSEA OR VOMITING	Journal of Toxicology, Clinical Toxicology. Vol. 38, Pg. 471, 2000.
women	TDLo	oral	549mg/kg (549mg/kg)	LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE	Japanese Journal of Acute Medicine. Vol. 20, Pg. 1557, 1996.